How do I hire a fractional revenue leader for a medical device company in 2027?

The job this role is actually hired to do

Most founders describe the need wrong on the first call. They say "we need someone to build the sales team," but what they usually mean is one of four distinct jobs, and hiring the wrong profile for the wrong job is where the money burns.

Job one: designing the commercial motion before it exists. The device is cleared, a handful of accounts came in through the founder's network or a clinical advisor's relationships, and now the company needs a repeatable path. This is a strategy job. The fractional leader spends the first month mapping the buying group, deciding whether the motion is direct rep, distributor, hybrid, or independent sales organization, and building the pricing and contracting architecture that everything downstream depends on. Companies get this wrong by hiring a strong closer who has never designed a channel, then wondering why month five looks like month one with more activity.

Job two: fixing a motion that exists but leaks. Reps are calling, demos are happening, evaluations are running, and almost nothing converts to a purchase order. This is an operational and RevOps job — stage definitions that mean something, exit criteria tied to actual procurement events, forecast discipline, territory design, and a CRM that reflects the real buying process rather than a generic B2B funnel. The diagnosis usually reveals the same thing: opportunities parked in "evaluation" for eight months because nobody defined what has to be true before an account can advance.

Job three: interim leadership during a gap. The VP left, a full-time search will take five to seven months, and the team needs someone accountable in the meantime. This is a stabilization job. The fractional leader runs the cadence, keeps forecast integrity intact, coaches the reps who are wobbling, and — critically — helps write the scorecard for the permanent hire. A good interim leaves behind a better job description than the one they inherited.

Job four: preparing for a specific event. A commercial launch tied to a clearance decision, a fundraise where the revenue story has to survive diligence, or a market entry into a new geography or care setting. This is a project job with a defined finish line, and it is often the cleanest fractional engagement because the scope is naturally bounded.

Be explicit about which job you are buying before you write a single outreach message. The screening questions, the reference checks, the deliverables, and the exit criteria all change depending on the answer. A candidate who is exceptional at job two may be mediocre at job one, and almost nobody is excellent at all four.

The adjacent reality worth naming: the same four-job framework applies in diagnostics, digital health, and life-sciences tooling, but the weight shifts. Diagnostics companies skew toward job one because reimbursement design dominates the go-to-market. Digital health companies skew toward job two because they generate volume quickly and leak it just as fast. Device companies with capital equipment skew toward job four, because the launch window around a clearance or a trade-show cycle is genuinely make-or-break.

Why medical device revenue leadership is a different discipline

The buying group is the first thing that breaks a generic playbook. In most B2B sales, you are managing an economic buyer, a technical evaluator, and maybe a procurement gate. In a hospital, you are managing a clinical champion who wants the device, a department head who owns the budget line, a value analysis committee that has to approve it, supply chain and procurement who negotiate the terms, biomedical engineering if it touches the network or the power grid, infection prevention if it is reusable, and legal if there is any data component. That is seven or more functions, each with veto power and none with unilateral buying authority.

Sales cycles reflect that structure. Six to eighteen months from first clinical contact to first purchase order is normal for a new capital device in a new account, and the clock is not evenly distributed — a deal can sit dormant for four months waiting for the next value analysis committee meeting, then move three stages in two weeks. A fractional leader who has only sold software will misread that pattern as a dead deal and coach the rep to walk away from something that was actually on track.

Then there is the fiscal-year overlay. Hospital capital budgets are set annually, often with a mid-year adjustment window, and a device that misses the capital cycle does not slip a quarter — it slips a year. Any credible fractional CRO will ask about your customers' fiscal calendars in the first week, because the entire forecast is shaped by them. If your target accounts run a July-to-June year, your Q1 is structurally weak and your Q4 is structurally strong, and building a plan that ignores this produces a forecast nobody can hit.

Capital versus consumables changes almost everything. If your revenue is a small number of high-value capital placements, your model depends on clinical evidence, reference sites, trial and evaluation logistics, and capital committee timing. Deal count is low, deal value is high, and a single slipped account can miss the quarter. If your revenue is consumables — catheters, cartridges, test kits, disposables — your model depends on formulary access, contract coverage, reorder behavior, and the density of accounts on contract. Deal count is high, deal value is low, and the leading indicator is not new logos but utilization per account. A fractional leader who conflates these will build the wrong compensation plan, the wrong CRM stages, and the wrong dashboard.

Many device companies run both simultaneously — a razor-and-blades model where the instrument is placed at low or zero margin and the recurring disposable carries the economics. That structure requires a leader who can hold two forecasting models at once and who understands placement economics: cost of the placed unit, expected utilization, breakeven month, and what happens when a placed instrument sits idle.

Contracting access is a gate, not a step. Group purchasing organizations and integrated delivery networks control which products a hospital's staff can easily buy. Getting onto contract is a multi-month process with its own evidence requirements, and being off-contract does not just make a sale harder — in many accounts it makes the sale procedurally impossible without an exception request that clinicians rarely want to fight for. A candidate who cannot describe how contract access works, what a value analysis submission contains, or how an exception request gets sponsored is not ready to run your revenue function.

Reimbursement sits upstream of everything. If your device is used in a procedure, whether that procedure is reimbursed, at what rate, and under which coding pathway determines whether an account can afford to adopt it regardless of clinical enthusiasm. In some categories the fractional leader's highest-leverage work is not sales coaching at all — it is building the economic case that lets a hospital finance team say yes. Ask candidates directly how reimbursement has shaped a go-to-market they have run. Vague answers here are disqualifying.

Regulatory status shapes the message, not just the label. What a rep may claim is constrained by what the clearance or approval covers. A leader who has lived inside a regulated commercial organization will instinctively route claims language through the right internal review, will know why the marketing team cannot simply publish a customer's off-label experience, and will build enablement materials that survive scrutiny. A leader who treats that as friction to route around is an active liability.

How the role fits the RevOps stack

A fractional revenue leader does not replace your RevOps function — they set its direction and then leave behind a system someone else can run. In practice the fit looks like this: the fractional leader owns the definitions, the operations person or agency owns the implementation, and the founder owns the decisions that require capital or clinical resources.

The system-of-record work is where most engagements produce their durable value. Medical device CRMs are frequently configured out of a generic B2B template, which means stages named "Qualification," "Proposal," and "Negotiation" that map to nothing that actually happens in a hospital. A competent fractional leader rebuilds those stages around real procurement events: clinical champion identified, evaluation scheduled, evaluation completed with documented outcome, value analysis submission filed, committee reviewed, contract vehicle confirmed, purchase order issued. Each stage gets an exit criterion that is objectively verifiable, which is what makes the forecast trustworthy.

Territory and account structure is the second pillar. In device sales, territory design is usually geographic and facility-based rather than industry-vertical, and it has to account for IDN structure — a single health system may have twenty facilities under one contracting umbrella, and splitting those across three reps guarantees a channel conflict inside your own team. The fractional leader should map account hierarchies before touching quotas.

Data hygiene has an unusual weight here because your accounts are enumerable. There are a finite number of hospitals, surgery centers, and labs in any given market. That means total addressable market is not a guess — it can be counted, segmented by procedure volume and facility type, and turned into a real coverage model. One of the fastest wins a fractional leader can deliver is replacing a vague TAM slide with a named-account list, tiered by fit, with coverage assigned and gaps visible.

The handoff at the end of that flow is the part companies forget to contract for. A fractional engagement that ends with the knowledge still in the leader's head has failed, no matter how good the numbers looked. Write the handoff artifacts into the statement of work: documented stage definitions, the named-account model, the forecast methodology, the enablement library, and a written scorecard for whoever comes next.

Adjacent to this sits marketing and clinical affairs. In device companies, the content that actually moves deals is clinical — evidence summaries, health-economic models, procedure guides, peer-to-peer programs. A fractional CRO who owns the full revenue function needs to coordinate with clinical and regulatory colleagues rather than direct a demand-generation team in isolation. If your candidate's marketing instinct is entirely digital-funnel, probe hard on how they would build a peer-to-peer evidence program instead.

Pricing, engagement models, and what the ranges depend on

Fractional revenue leadership is typically priced as a monthly retainer tied to a committed day count rather than an hourly rate, and the market spread is wide enough that any single number quoted as "the going rate" should be treated skeptically. What you can reason about reliably are the variables that move the price.

Day commitment is the primary driver. Engagements commonly run between eight and twenty days per month. Below eight days, the leader cannot maintain a real cadence in a business with six-to-eighteen-month cycles — they arrive, review a pipeline that has barely moved, and leave. Ten to twelve days is the common floor for meaningful strategic work. Fifteen to twenty days approaches near-full-time engagement and is usually reserved for interim leadership where the person is genuinely running the function day to day.

Scope breadth is the second driver. A leader owning only sales costs less than one owning sales, marketing, customer success, and channel. A leader who is also expected to personally carry key accounts, negotiate a GPO agreement, or represent the company at clinical conferences is doing work that would otherwise require additional headcount, and the price should reflect that.

Specialization premium is real and worth paying. The pool of operators who have genuinely run commercial organizations in regulated device businesses is small. Someone who has taken a Class II device from clearance to a national contract portfolio commands more than a generalist fractional CRO, and the premium is usually cheaper than the cost of a generalist's learning curve — which you pay for in months, not dollars, and months are the expensive currency in device sales.

Structure options worth knowing:

*Straight monthly retainer.* Simplest and most common. Fixed fee, fixed day commitment, monthly invoicing. Best for interim and operational engagements where the value is continuity.

*Retainer plus milestone bonus.* A base retainer with additional payment triggered by defined outcomes — first contract with a named IDN, pipeline coverage reaching a specified multiple, a completed and adopted revenue plan, a specific number of accounts moved past evaluation. This aligns incentives without pretending a fractional leader controls the whole outcome. Keep milestones to three or fewer and make each objectively measurable, or you will spend the engagement arguing about definitions.

*Project or sprint pricing.* A fixed fee for a defined deliverable — a go-to-market plan, a channel strategy, a pricing architecture, a commercial readiness assessment ahead of a launch. Clean, bounded, and the right structure when you know exactly what artifact you need.

*Equity participation.* Uncommon as the primary compensation and generally a warning sign if a candidate pushes for it early, because it usually signals they cannot fill their book with cash engagements. It becomes reasonable as a supplement when the fractional leader is genuinely co-building the commercial organization over a long horizon and the company is deliberately trading cash for alignment. If you do it, use standard advisor vesting with a cliff, and get it papered properly.

*Commission or revenue share.* Rarely appropriate for a fractional leader and structurally awkward in device sales, where the leader's influence on any individual deal is diffuse and the cycle length means commissions would land long after the engagement ended. If a candidate proposes this as the core structure, they are probably positioning themselves as a rep rather than a leader.

Terms that protect both sides: a thirty-day mutual termination clause, a defined day-count with a documented process for overages, clarity on travel and expense treatment (device work involves real travel — hospital visits, clinical observations, trade shows), IP assignment covering the materials they build for you, and a non-solicit that does not accidentally prevent them from working with other non-competing device companies. Fractional leaders serve multiple clients by definition; a non-compete broad enough to block their practice will either be rejected or will price you at a premium you did not intend to pay.

Budget the total, not the retainer. The retainer is one line. Add travel, any tooling the leader will require, potential contractor support for CRM implementation, and the cost of your own team's time in the cadence they will install. Companies that budget only the retainer are surprised in month two.

How to evaluate and shortlist candidates

Start by writing the scorecard before you meet anyone. Three to five outcomes, each measurable, each achievable inside the engagement window. "Improve sales" is not a scorecard entry. "Move eight named target accounts from clinical interest to a filed value analysis submission within ninety days" is.

Sourcing. The best fractional device operators are rarely on job boards. They come from three places: your investors' networks, which are usually the highest-signal source because the introduction carries accountability; fractional executive networks and communities, which offer vetting and breadth; and your own industry graph — former colleagues, distributor principals, clinical advisors who have watched commercial leaders operate up close. Ask three device founders in your investor's portfolio who they would call. The same two or three names surface quickly in most categories.

Screening for real device experience. Generic questions produce generic answers. Use scenarios instead:

• "Walk me through getting a new Class II device into a large health system where we have zero relationships. Who do you contact first, what does the first meeting look like, what documents do you need ready, and what is the realistic timeline to first order?" A real operator answers with sequence and artifacts. A generalist answers with adjectives.
• "We are off-contract at a major IDN and a surgeon wants our device. What actually happens next?" You are listening for a concrete description of the exception or sponsorship process, not enthusiasm.
• "Our evaluations convert at a rate we are unhappy with. Before you change anything, what do you look at?" Strong answers start with how evaluations are structured and who is accountable for the outcome, not with rep coaching.
• "How would you structure the sales process differently for a capital placement versus a high-volume disposable?" This single question separates people who have run device revenue from people who have read about it.
• "Tell me about a time a claim you wanted to make in sales collateral got stopped. What did you do?" Anyone who has operated inside a regulated commercial organization has this story. Absence of the story is information.

The paid diagnostic pilot. This is the highest-value step in the entire process and almost nobody skips it twice. Two to four weeks, paid at the candidate's normal rate, with a defined deliverable: a written assessment of your pipeline, process, team, and data, plus a prioritized ninety-day plan. You learn how they think, how they interact with your team, whether they ask good questions, and whether their written work is any good. They learn whether your business is one they can actually help. Both sides get an honest exit ramp. Run pilots with two finalists in parallel if the stakes justify it — the comparison is instructive and the cost is small next to a failed six-month engagement.

Reference calls that produce signal. Ask for references from device or diagnostics companies specifically, and ask for at least one engagement that did not go well. The questions that work: "What did they change that stuck after they left?" "Where did they push back on you, and were they right?" "What did they not do that you wished they had?" "Would you hire them again for the same job, or a different one?" The last question is unusually revealing — a reference who would rehire them for a different job is telling you something precise about their range.

Network diligence. In device sales, a leader's existing relationships with health systems, distributors, contracting organizations, and clinical key opinion leaders have direct commercial value. But test it rather than accepting it. "Which three accounts could you get us a real conversation in within sixty days, and who specifically would you call?" A candidate with a genuine network names people. A candidate without one names categories.

Watch for these failure signals: a portfolio entirely outside regulated industries, described as transferable; dismissiveness about regulatory or reimbursement constraints as "friction"; unwillingness to do a paid pilot; a pitch centered on their methodology rather than your situation; day commitments so thin they cannot possibly maintain cadence; and a book of clients so full that you are clearly the eighth priority. Ask directly how many concurrent engagements they carry. Three is normal. Six is a red flag.

A buyer decision framework you can run this week

The decision is not simply "fractional or full-time." It is a sequence of gates, and each one has a defensible answer.

Gate one: is the problem strategy or execution? If your motion is undefined or wrong, a fractional leader is often the better first move — you buy senior judgment without committing to a permanent seat before you know what that seat should be. If your motion is defined and the problem is that people are not running it, you may need a full-time manager who is present daily, not a strategist who visits.

Gate two: how large is the team? Below roughly eight to ten revenue people, a fractional leader can realistically provide direction, coaching, and cadence. Above that, the daily management load — one-on-ones, escalations, hiring, performance issues, cross-functional firefighting — exceeds what ten to twenty days a month can absorb. At that scale, hire full-time and consider a fractional advisor alongside for a specific gap like channel design.

Gate three: what is the runway and the funding stage? Pre-revenue or early commercial companies with tight runway benefit from the flexibility — no severance exposure, no equity dilution, a thirty-day exit. Companies with capital and a defined multi-year plan often get better economics from a permanent hire whose incentives compound.

Gate four: is there an event on the calendar? A clearance decision, a launch, a fundraise, or a market entry creates a bounded window where senior help has outsized value. That is close to the ideal fractional use case.

Gate five: can your organization absorb a part-time leader? This one gets skipped and it matters most. A fractional leader needs a decision-maker who is responsive, a team willing to be coached by someone who is not there every day, and at least one internal owner for implementation. If your founder is unavailable for weeks at a time or your team treats an outside leader as an intruder, the engagement will fail regardless of the candidate's quality.

The ninety-day review. Judge the engagement on questions that have factual answers. Is there a written revenue plan the team can recite? Has pipeline coverage improved against a stated multiple, and is the pipeline built from opportunities with verified exit criteria rather than optimism? Have specific accounts advanced through real procurement gates — evaluations completed, submissions filed, contracts confirmed? Is the forecast more accurate than it was, even if the number is lower? Are your reps operating from a common methodology? Has the leader built at least one relationship that did not exist before, with a clinical champion, a contracting contact, or a distributor principal?

A lower forecast that turns out to be accurate is a win, not a failure. One of the most common and most valuable outcomes of a good fractional engagement is discovering that the pipeline was never real, which is painful in month two and enormously cheaper than discovering it in month ten.

If most answers are no after ninety days, end it. The thirty-day clause exists for this. Before hiring a replacement, re-diagnose — a second failed engagement usually means the problem was misdiagnosed rather than the candidate mismatched. Common re-diagnoses: the product is not yet clinically differentiated enough to sell, reimbursement is not in place, or the founder is unwilling to relinquish commercial decisions, which no external leader can fix.

Related questions

What does a fractional CRO actually deliver in the first 30 days?

A written revenue plan grounded in a diagnostic of pipeline, process, team, and data. Expect rebuilt CRM stage definitions with real exit criteria, a named-account and coverage model, an honest reforecast, and a prioritized ninety-day plan the team has reviewed and can execute.

Should I hire a fractional CRO or a fractional VP of Sales?

A CRO owns the full revenue function — sales, marketing, customer success, and channel — and is right when go-to-market design, pricing, or channel strategy is the gap. A VP of Sales owns team execution. Small companies needing motion design want the CRO.

Can a fractional revenue leader work remotely for a device company?

Partially. Strategy, cadence, forecasting, and RevOps work fine remotely, but device sales requires in-person presence for clinical observations, hospital visits, key account meetings, and conferences. Budget at least several days on site or in the field each month and write travel into the agreement.

How do I know if my pipeline problem is real before hiring anyone?

Check whether each open opportunity has a documented next procurement event with a date and an owner. Opportunities without one are not pipeline. If most of yours fail that test, you have a qualification problem a fractional leader can fix quickly.

What happens to the engagement when I hire a full-time leader?

Plan the overlap deliberately. The fractional leader should help write the scorecard, participate in interviews, then run a structured handoff of account context, stage definitions, forecast methodology, and relationships. Thirty to sixty days of overlap at reduced days is common and worth the cost.

FAQ

How much does a fractional revenue leader cost for a medical device company?

Pricing is normally a monthly retainer tied to a committed day count — commonly eight to twenty days per month — rather than an hourly rate, and the range varies widely by scope, seniority, and specialization. Cost rises with breadth of ownership, with regulated-industry specialization, and with any expectation that the leader personally carries key accounts or negotiates contracting agreements. Ask for pricing broken out by day commitment and scope so you can compare candidates on the same basis, and budget travel separately.

How long should the engagement run?

Three to twelve months is the normal window, with a paid two-to-four-week diagnostic in front of it. Anything shorter than three months rarely produces measurable change in a business with six-to-eighteen-month sales cycles — you get a plan but not evidence it works. Engagements past twelve months usually mean one of two things: the arrangement has quietly become a permanent part-time role, which is fine if intentional, or the underlying problem was never a leadership problem.

What if the candidate has device experience but not in my specific category?

Adjacent category experience usually transfers well. Someone who sold surgical capital equipment can learn a new specialty; someone who sold only software cannot easily learn hospital procurement. What matters is fluency with the buying group, contracting access, evidence requirements, and reimbursement dynamics. Probe how quickly they build clinical understanding — ask what they did in their first month at their last company to get credible with clinicians, and whether they can explain your device's clinical value after two conversations.

Do I need a fractional leader if I already have a RevOps person?

Often yes, because they solve different problems. A RevOps person builds and maintains systems, reporting, and process mechanics. A fractional revenue leader decides what the motion should be, what the stages mean, how territories are structured, and where the company should focus. The best pairing is a fractional leader setting direction and an internal RevOps owner implementing it. Hiring only RevOps when the strategy is undefined produces well-instrumented reporting on a motion nobody has decided.

Can one fractional leader cover both a device line and a services or software line?

Yes, if they have run mixed models before, but confirm it explicitly. Companies selling an instrument plus disposables plus a software or service layer need someone who can hold multiple revenue models at once — placement economics, recurring consumable volume, and subscription retention each have different leading indicators, comp structures, and forecast mechanics. Ask a candidate to sketch how they would report on all three in one board deck. The answer tells you quickly whether they have done it.

What is the single biggest reason these engagements fail?

Unclear scope combined with an unavailable decision-maker. A fractional leader with a vague mandate and a founder who is traveling for three straight weeks will produce documents nobody acts on. The fix is unglamorous: a written scorecard with three to five measurable outcomes, a standing weekly meeting with the founder that does not get cancelled, and one internal owner responsible for implementing what the leader designs.

Sources

• U.S. Food and Drug Administration — Medical Device Overview
• FDA — 510(k) Premarket Notification
• Centers for Medicare & Medicaid Services
• AdvaMed — Advanced Medical Technology Association
• Vizient
• Premier Inc.
• Harvard Business Review
• MedTech Dive
• Association for Health Care Resource & Materials Management (AHRMM)

Related on PULSE

• How do I structure a fractional CRO engagement?
• What does a RevOps leader own in a regulated industry?
• How do I build a pipeline coverage model for long sales cycles?
• Fractional CRO vs. full-time VP of Sales: how to choose
• How do I design sales territories around health system accounts?